Compositions and methods related to prevention and treatment of rabies infection
A technology for rabies and rabies virus, applied in the field of preparation of anti-rabies antibodies, can solve the problems of interfering with vaccine antigenicity, reducing efficacy and the like
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example
[0161] In order to more fully illustrate selected embodiments of the invention, the following examples are presented. These examples should in no way be construed as limiting the scope of the invention as defined by the following claims.
example 1
[0163] Example 1 - Preparation and Characterization of Murine Rabies Virus Neutralizing Antibodies
[0164] Murine rabies virus neutralizing antibodies can be obtained by culturing hybridomas which in turn can be obtained by immunizing mice with rabies glycoprotein and subsequently fusing spleen cells or lymph node cells from the mice containing mouse myeloma cells. Referring to the above steps, the procedure for preparing anti-rabies antibodies is described in detail below. This method of producing the antibody of the present invention is merely illustrative of the production method and is not limited thereto. Other known procedures can be followed.
[0165] The present invention utilizes rabies virus glycoprotein (Genbank Accession No. ABY1950) as an immunogen for inducing antibodies capable of neutralizing rabies virus. The prepared immunogen is mixed with an adjuvant (eg, Freund's complete or incomplete adjuvant) and administered to mice. Suitable routes of administrati...
example 2
[0171] Binding activity of example 2-murine rabies virus neutralizing antibody
[0172] In this example, the binding activity of five rabies virus neutralizing antibodies (RVNA) to the rabies virus RV glycoprotein was investigated. The murine RVNA and other biological materials used in Examples 1-6 are shown in Table 3. Animals used in these studies included BALB / c mice, female, 6-8 weeks, weighing 20 to 30 grams, SPF; and Syrian hamsters, 2-3 months, weighing 100 grams, SPF.
[0173]
[0174] Binding curves of five RVNAs to RV glycoproteins as determined by indirect chemiluminescence enzyme immunoassay (CLEIA) are shown in figure 1 middle. Glycoproteins were diluted 1:500 in PBS and then coated with microplates. The five clones of RVNA were diluted to 10000, 2000, 400, 80, 16, 3.2 and 0.64 ng / mL, respectively. Goat anti-mouse IgG2a-FIRP and goat anti-mouse IgG2b-FIRP were used as enzyme-conjugated secondary antibodies. Relative luminescence units (RLU) represent the c...
PUM
Property | Measurement | Unit |
---|---|---|
diameter | aaaaa | aaaaa |
purity | aaaaa | aaaaa |
purity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com